Platelet activation during angiotensin II infusion in healthy volunteers

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 1, 2000, Pages 61-69

  Larsson, P Thomas ^a,d   Schwieler, J H ^b   Wallen N H ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Angiotensin II; Coagulation; Flow cytometry; Platelet function; thromboglobulin

Indexed keywords

ANGIOTENSIN; BETA THROMBOGLOBULIN; CATECHOLAMINE; FIBRINOGEN; PADGEM PROTEIN; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ARTICLE; BLOOD CLOTTING; FLOW CYTOMETRY; HUMAN; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

EID: 0033960455     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200011010-00007     Document Type: Article

References (34)

1. 1. Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993; 14:205-212.
2. 2. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JGF. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994; 127: 607-612.
3. 3. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-1435.
4. 4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
5. 5. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-677.
6. 6. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
7. 7. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
8. 8. Someya N, Moromoti Y, Kodama K, Kida O, Higa T, Kondo K, et al. Suppressive effect of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol 1984; 6: 840-843.
9. 9. James IM, Dickenson EJ, Burgoyne W, Jeremy JY, Barradas MA, Mikhailidis DP, et al. Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation. J Human Hypertens 1988; 2: 21-25.
10. 10. Islim IF, Beevers DG, Bareford D. The effect of antihypertensive drugs on in vivo platelet activity in essential hypertension. J Hypertens 1992; 10: 379-383.
11. 11. Birkebaek NH, Vejby-Christensen H, Jakobsen P, Winther K. The effect of nifedipine and captopril on platelet activation and prostanoid production in essential hypertension. J Hypertens 1988; 6(suppl 4): S378-S380.
12. 12. Gupta RK, Kjeldsen SE, Motley E, Weder AB, Zweifler AJ, Julius S. Platelet function during anti-hypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor. J Cardiovasc Pharmacol 1991; 17: 13-19.
13. 13. Zannad F, Bray-Desboscs L, El Ghavi R, Donner M, Thibout E, Stoltz J-F. Effects of lisinopril and hydrochlorthiazide on platelet function and blood rheology in essential hypertension: a randomly allocated double-blind study. J Hypertens 1993; 11: 559-564.
14. 14. Moore TJ, Williams GH. Angiotensin II receptors on human platelets. Circ Res 1981; 51: 314-320.
15. 1 receptors on human platelets and decreased angiotensin II binding in hypertension. J Hypertens 1993; 11(suppl 5):S230-S231.
16. 16. Ding YA, MacIntyre DE, Kenyon CJ, Semple PF. Potentiation of adrenaline-induced platelet aggregation by angiotensin II. Thromb Haemost 1985; 54: 717-720.
17. 17. Swartz SL, Moore TJ. Effect of angiotensin II on collagen-induced platelet activation in normotensive subjects. Thromb Haemost 1990; 63: 87-90.
18. 2+ concentrations in essential hypertension. Hypertens 1993; 22: 853-862.
19. 19. Hornstra G, ten Hoor F. The filtragometer: a new device for measuring platelet aggregation in venous blood of man. Thromb Diath Haemorrh 1975; 34: 531-544.
20. 20. Duggan J, Nussberger J, Kilfeather S, O'Malley K. Aging and human hormonal and pressor responsiveness to angiotensin II infusion with simultaneous measurement of exogenous and endogenous angiotensin II. Am J Hypertens 1993; 6: 641-647.
21. 21. Nussberger J, Brunner DB, Waeber B, Brunner HR. Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension 1986; 8: 476-482.
22. 22. Janes SL, Wilson DJ, Chronos N, Goodall AH. Evaluation of whole blood flow-cytometric detection of platelet bound fibrinogen on normal subjects and patients with activated platelets. Thromb Haemost 1993; 70: 659-666.
23. 23. Michelson AD. Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications. Blood Coag Fibrinol 1994; 5: 121-131.
24. 24. Larsson PT, Hjemdahl P, Olsson G, Egberg N, Hornstra G. Altered platelet function during mental stress and adrenaline infusion in humans: evidence for an increased aggregability in vivo as measured by filtragometry. Clin Sci 1989; 76: 369-376.
25. 25. Hjemdahl P. Catecholamine measurements in plasma by high-performance liquid chromatography with electrochemical detection. Methods Enzymol 1987; 142:521-534.
26. 26. Larsson PT, Wallén NH, Egberg N, Hjemdahl P. α-Adrenoceptor blockade by phentolamine inhibits adrenaline-induced activation in vivo without affecting resting measurements. Clin Sci 1992; 82: 369-376.
27. 27. Dawes J, Smith RC, Pepper DS. The release, distribution, and clearance of human β-thromboglobulin and platelet factor 4. Thromb Res 1978; 12: 851-861.
28. 28. Michelson AD, Barnard MR, Hechtman HB, Mac-Gregor H, Connolly RJ, Loscalzo J, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci 1996; 93: 11877-11882.
29. 29. Bauer KA, Goodman TL, Kass BL, Rosenberg RD. Elevated factor Xa activity in the blood of asymtomatic patients with congenital antithrombin deficiency. J Clin Invest 1985; 76: 826-836.
30. 30. Shifman MA, Pizzo SV. The in vivo metabolism of antithrombin III and antithrombin complexes. J Biol Chem 1982; 257: 3243-3248.
31. 31. Furie B, Furie BC. Leucocyte crosstalk at the vascular wall. Thromb Haemost 1997; 78: 306-309.
32. 32. Krejcy K, Eichler HG, Jilma B, Kapiotis S, Wolzt M, Zanaschka G, et al. Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo. Can J Physiol Pharmacol 1996; 74: 9-14.
33. 33. Grafe M, Auch-Schwelk W, Zakrzewicz A, Regitz-Zagrosek V, Bartsch P, Graf K, et al. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res 1997; 81: 804-811.
34. 34. Ross R, Fuster V. The pathogenesis of atherosclerosis. In: Fuster V, Ross R, Topol EJ (editors): Atherosclerosis and coronary artery disease. Philadelphia, PA: Lippincott-Raven Publishers; 1996. pp. 441-460.